Search
Risdiplam
go.drugbank.com/drugs/DB15305ApprovedInvestigationalThis mechanism of action is similar to its predecessor [nusinersen], the biggest difference being their route of administration: nusinersen requires intrathecal administration, as does the one-time gene … [L15351,A216871] Risdiplam was approved by the FDA in August 2020 for the treatment of spinal muscular atrophy (SMA).
Sinecatechins
go.drugbank.com/drugs/DB01266ApprovedInvestigationalNutraceuticalThe remaining amount of the drug substance contains undefined botanical constituents derived from green tea leaves. … It is a partially purified fraction of the water extract of green tea leaves from Camellia sinensis, and is a mixture of catechins and other green tea components.
Synonyms: Polyphenon EGolodirsen
go.drugbank.com/drugs/DB15593ApprovedInvestigationalOften, patients succumb to this condition by age 30 or younger due to cardiac and respiratory complications. … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of
Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalLusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan). … Lusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta.
Categories: Thrombopoietin Receptor AgonistIndium In-111 pentetreotide
go.drugbank.com/drugs/DB11835ApprovedIndium In 111 pentetreotide (Octreoscan) has been used in trials studying the diagnostic of SARCOIDOSIS, Solid Tumors, and cushing syndrome.
Mixtures: Kit for the Preparation of Indium In 111 PentetreotideLinagliptin
go.drugbank.com/drugs/DB08882ApprovedInvestigationalLinagliptin was approved by the FDA on May 2, 2011[L9557]. … Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes [L9557].
Histrelin
go.drugbank.com/drugs/DB06788ApprovedInvestigationalWithdrawn[L41715] The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. … As the product Supprelin LA, histrelin is indicated for the treatment of CPP in children (approved by the FDA in May 2007).[L41700]
Categories: Gonadotropin Releasing Hormone Receptor Agonist, Gonadotropin Releasing Hormone Receptor AgonistsNisoldipine
go.drugbank.com/drugs/DB00401ApprovedNisoldipine may be used in alone or in combination with other agents in the management of hypertension. … By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction.
International brands: Ji Ni Le ErEnsifentrine
go.drugbank.com/drugs/DB16157ApprovedInvestigationaldirectly delivered to the lungs. … [L50903] On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD) in adults, which allows the drug to be
Synonyms: N-(2-((2E)-9,10-DIMETOXI-4-OXO-2-((2,4,6-TRIMETILFENIL)IMINO)-6,7-DIHIDRO-2H-PIRIMIDO(6,1-A)ISOQUINOLEIN-3(4H)-IL)ETIL)UREAMetronidazole
go.drugbank.com/drugs/DB00916ApprovedInvestigationalMetronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. … It is available in capsule form, tablet form, and topical form, and suppository preparations for the treatment of various infections.